Macitentan: a review of its use in patients with pulmonary arterial hypertension.

about

Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel.Exploiting drug repositioning and the brain microenvironment to treat brain metastases.

P2860

Q36705944-EF7C4DE0-AF4F-4EA3-93B2-C268F2E58C9A Q42944473-D960B025-D200-42C0-AF14-641DE89B60BB

P2860

Macitentan: a review of its use in patients with pulmonary arterial hypertension.

Item

http://www.wikidata.org/entity/Q38233833

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Macitentan: a review of its use in patients with pulmonary arterial hypertension.

@en

type

Item

label

Macitentan: a review of its use in patients with pulmonary arterial hypertension.

@en

prefLabel

Macitentan: a review of its use in patients with pulmonary arterial hypertension.

@en

P1476

Macitentan: a review of its use in patients with pulmonary arterial hypertension.

@en

P2093

Sohita Dhillon

http://www.w3.org/2001/XMLSchema#string

P2860

Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells

Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial.

Pulmonary arterial hypertension in France: results from a national registry.

Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.

Pathways in pulmonary arterial hypertension: the future is here.

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American Co

Diagnosis and assessment of pulmonary arterial hypertension.

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In

The endothelin system in pulmonary arterial hypertension.

Cellular and molecular pathobiology of pulmonary arterial hypertension.

P2888

s40265-014-0266-9

P304

1495-1507

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-014-0266-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264248078

http://www.w3.org/2001/XMLSchema#string

P6179

1033909711

http://www.w3.org/2001/XMLSchema#string

P698

25060980

http://www.w3.org/2001/XMLSchema#string

Macitentan: a review of its use in patients with pulmonary arterial hypertension.

about

P2860

P2860

Macitentan: a review of its use in patients with pulmonary arterial hypertension.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P6179

P698